The FDA sent a Warning Letter to Sprout Pharmaceuticals alleging an Instagram post by the company’s chief executive officer about Addyi failed to include any risk information and omitted information on the drug’s full indication, including limitations on its use. The May 29 Warning Letter from FDA’s Office of Prescription Drug Promotion (OPDP) also alleged the company had not... Read More